期刊文献+

WHO 2014年版《耐药结核病规划管理指南伙伴手册》系列解读之七(耐多药与广泛耐药结核病的治疗) 被引量:7

下载PDF
导出
摘要 耐药结核病的流行是当前结核病控制工作面临的主要挑战之一,严重威胁人们在结核病控制领域所取得的成就。抗结核药物是控制结核病的最有效武器,但面对耐多药结核病(MDR-TB)尤其是广泛耐药结核病(XDR-TB)明显力不从心,结核病有可能因此而再度成为“不治之症”[1]。
出处 《中国防痨杂志》 CAS 2015年第7期800-802,共3页 Chinese Journal of Antituberculosis
  • 相关文献

参考文献4

  • 1肖和平,方勇,范琳,刘一典.耐药结核病化学治疗研究的过去、现状与未来[J].中国防痨杂志,2014,36(8):634-637. 被引量:12
  • 2World Health Organization. Companion handbook to the WHO guideline for the programmatic management of drug-re- sistant tuberculosis. WHO/HTM/TB/2014. 11. Geneva: World Health Organization, 2014.
  • 3World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008. 402. Geneva:World Health Or- ganization, 2008.
  • 4World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. WHO/HTM/TB/2011.6. Geneva: World Health Organiza- tion, 2011.

二级参考文献22

  • 1肖和平.耐多药结核病化疗药物的选择与方案的制定[J].中华结核和呼吸杂志,2006,29(8):517-519. 被引量:32
  • 2Grosset J. The sterilizing value of rifarnpicin and pyrazinamide in experimental short course chemotherapy. Bull Int Union Tu bert, 1978,53(1):5-12.
  • 3[No authors listed]. Controlled elinieal trial of four shorv course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils. Lancet, 1974, 2(7875) :237-240.
  • 4World Health Organization. Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96. 210. Geneva: World Health Organization, 1996.
  • 5World Health Organization. Glohal tuberculosis report 2013. Geneva: World Health Organization, 2013.
  • 6Sbarbaro JA, Iseman MD, Crowle AJ. Combined effect of pyraziamide and ofloxaein within the human maerophage. Tu ber LunR Dis, 1996, 72(6):491-495.
  • 7World Health Organization. Guidelines for the programmatic- management of drug-resistant tuberculosis. 2011 update. WHO/HTM/TB/2011.6. Geneva: World Health Organiza- tion, 2011.
  • 8Sullivan EA, Kreiswirth BN, Palumbo L, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lan- cet, 1995,345(8958) : 1148-1150.
  • 9World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/ 2006. 361. Geneva: World Health Organization, 2006.
  • 10Nuermberger EL, Spigelman MK, Yew WW. Current develop- ment and future prospects in chemotherapy of tuberculosis. Re- spirology, 2010,15 (5) : 764-778.

共引文献11

同被引文献63

  • 1韦琪平.耐多药结核病研究进展[J].医学信息(医学与计算机应用),2014,0(22):670-670. 被引量:3
  • 2谷金莲,祁自柏,扬振,于洋,张华远,李河民.第5套丙型肝炎病毒抗体诊断试剂国家参考品的研制[J].中国生物制品学杂志,2006,19(1):68-70. 被引量:20
  • 3端木宏谨.耐药结核病的流行和监测[J].中华结核和呼吸杂志,2006,29(8):509-511. 被引量:38
  • 4Dr. Karel Styblo Symposium: An Emerging Global Programme Against Tuberculosis. The Hague, March 15, 1991. Bull Int Union Tuberc Lung Dis, 1991, 66(4) : 139-214.
  • 5Frieden TR, Munsiff SS. The DOTS strategy for controlling the global tuberculosis epidemic. Clin Chest Med, 2005, 26 (2) : 197-205, v.
  • 6Wang L, Zhang H, Ruan Y,et al. Tuberculosis prevalence in China, 1990 -2010; a longitudinal analysis of national survey data. Lancet, 2014, 383(9934):2057-2064.
  • 7World Health Organization. The stop TB strategy. Building on and enhancing DOTS to meet the TB-related Millennium De- velopment Goals, Geneva: World Health Organization,2006.
  • 8World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis 2008 urgent ver sion. Geneva: World Health Organization, 2008.
  • 9Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis, 198(3,133(3) : 423-430.
  • 10Espinal MA, Kim SJ, Suarez PG, et al. Standard short course chemotherapy for druresistant tuberculosis: treatment out- comes in 6 countries. JAMA, 2000, 283 (19):2537-2545.

引证文献7

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部